How are you going to trade this breakout inside the gap? goo.gl/jGvOaX
Ariad Pharmaceuticals Inc., the cancer-drug maker that had lost about 70 percent of its value this year, will return its only product (cleared last year for certain types of leukemia) to the U.S. market after regulators approved a new prescribing and risk management plan.
Sales of the drug were halted in the U.S. in October after regulators saw an increased risk of blood clots.
www.businessweek.com...rug-back-to-market-1
If October's gap down is filled, a long position opened today with a $4.50 stop loss has a potential Risk/Reward ratio of 2.
What do you think of the gap at the ARIA stock chart?
Ariad Pharmaceuticals Inc., the cancer-drug maker that had lost about 70 percent of its value this year, will return its only product (cleared last year for certain types of leukemia) to the U.S. market after regulators approved a new prescribing and risk management plan.
Sales of the drug were halted in the U.S. in October after regulators saw an increased risk of blood clots.
www.businessweek.com...rug-back-to-market-1
If October's gap down is filled, a long position opened today with a $4.50 stop loss has a potential Risk/Reward ratio of 2.
What do you think of the gap at the ARIA stock chart?